What is the treatment for Cushing's syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Cushing's Syndrome

Surgical resection of the causative tumor is the first-line treatment for all forms of endogenous Cushing's syndrome, with medical therapy reserved for cases where surgery is not an option or has not been curative. 1

Diagnostic Approach

Before initiating treatment, proper diagnosis is essential:

  • Confirm hypercortisolism using 24-hour urinary free cortisol (UFC), late-night salivary cortisol (LNSC), or overnight 1 mg dexamethasone suppression test (DST) 1
  • Determine ACTH dependency status to identify the source 1
  • For ACTH-dependent cases, perform pituitary MRI and potentially inferior petrosal sinus sampling (IPSS) to differentiate pituitary from ectopic sources 1
  • For ACTH-independent cases, adrenal imaging is required to identify adrenal adenomas, carcinomas, or bilateral hyperplasia 1

Treatment Algorithm

1. ACTH-Dependent Cushing's Syndrome (Cushing's Disease)

First-line: Surgical Treatment

  • Transsphenoidal surgery (TSS) for pituitary adenomas 1
  • Surgical resection of ectopic ACTH-producing tumors when identified and accessible 1

Second-line: Medical Therapy (if surgery fails or is not an option)

Adrenal Steroidogenesis Inhibitors:

  • Ketoconazole: 400-1200 mg/day in divided doses; ~65% UFC normalization; monitor for hepatotoxicity and drug interactions 1
  • Metyrapone: 500 mg/day to 6 g/day in divided doses every 6-8 hours; ~70% UFC normalization; monitor for hirsutism, hypertension, and hypokalemia 1
  • Osilodrostat: 2-7 mg twice daily (maximum 30 mg twice daily); 86% UFC normalization in phase 3 trials; FDA approved for CD when surgery is not an option 1
  • Mitotane: 250-500 mg/day up to 8 g/day; ~80% UFC normalization; slow onset of action; teratogenic 1

Pituitary-Directed Therapy:

  • Pasireotide: 0.3-0.9 mg twice daily; 15-26% UFC normalization; monitor for hyperglycemia 1, 2

Glucocorticoid Receptor Antagonist:

  • Mifepristone: Starting dose 300 mg once daily, can be increased to maximum of 1200 mg/day based on weight and response; improves glucose control and clinical features 3

Third-line Options:

  • Pituitary radiation therapy with concurrent medical therapy 4
  • Bilateral adrenalectomy for refractory cases 1, 4

2. ACTH-Independent Cushing's Syndrome

Adrenal Adenoma or Unilateral Disease:

  • Laparoscopic adrenalectomy of the affected gland 1
  • Postoperative glucocorticoid supplementation until HPA axis recovery 1

Adrenal Carcinoma:

  • Open adrenalectomy with lymph node dissection 1
  • Consider adjuvant mitotane therapy and radiation for high-grade tumors 1

Bilateral Adrenal Hyperplasia:

  • If cortisol production is asymmetric: unilateral adrenalectomy of the most active side 1
  • If cortisol production is symmetric: medical management with steroidogenesis inhibitors 1

Special Considerations

Acute Severe Hypercortisolism

  • Etomidate: 0.04-1 mg/kg/h IV for rapid control in ICU setting; requires careful monitoring 1

Hypertension Management in Cushing's Syndrome

  • Mineralocorticoid receptor antagonists (spironolactone, eplerenone) are particularly effective 1
  • Multiple antihypertensive agents often required due to multiple pathways of hypertension in Cushing's syndrome 1

Pediatric Considerations

  • Surgical approach is still first-line, but thromboprophylaxis should be used more selectively 1
  • For medical therapy, ketoconazole or metyrapone are preferred; pasireotide is not recommended 1
  • Growth hormone deficiency assessment within 3-6 months post-surgery 1

Monitoring and Follow-up

  • Regular assessment of cortisol levels (UFC, morning serum cortisol) to evaluate treatment efficacy 1
  • Monitor for specific medication side effects (liver function with ketoconazole, electrolytes with metyrapone) 1
  • Address comorbidities: diabetes, hypertension, osteoporosis, and psychiatric symptoms 1

Common Pitfalls

  • Failure to recognize cyclical Cushing's syndrome, which may require repeated testing 1
  • Inadequate treatment of comorbidities, which contribute significantly to morbidity and mortality 1
  • Drug interactions with ketoconazole and other steroidogenesis inhibitors 1
  • Adrenal insufficiency risk with medical therapy, requiring careful dose titration 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cushing syndrome.

Nature reviews. Disease primers, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.